These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 2369685

  • 1. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
    Baglin TP, Harper P, Marcus RE.
    Bone Marrow Transplant; 1990 Jun; 5(6):439-41. PubMed ID: 2369685
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Successful treatment of veno-occlusive disease with recombinant tissue plasminogen activator in a patient requiring peritoneal dialysis.
    Simpson DR, Browett PJ, Doak PB, Palmer SJ.
    Bone Marrow Transplant; 1994 Oct; 14(4):635-6. PubMed ID: 7858540
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
    Bajwa RP, Cant AJ, Abinun M, Flood TJ, Hodges S, Hale JP, Skinner R.
    Bone Marrow Transplant; 2003 Apr; 31(7):591-7. PubMed ID: 12692627
    [Abstract] [Full Text] [Related]

  • 7. Fatal hemorrhage after recombinant tissue plasminogen activator therapy for hepatic veno-occlusive disease complicating autologous BMT.
    Otheo de Tejada E, Maldonado MS, Camarero C, Muñoz A.
    Bone Marrow Transplant; 1994 Jul; 14(1):176-7. PubMed ID: 7951113
    [No Abstract] [Full Text] [Related]

  • 8. Veno-occlusive disease of the liver complicating bone marrow transplantation.
    Baglin TP.
    Bone Marrow Transplant; 1994 Jan; 13(1):1-4. PubMed ID: 8019444
    [Abstract] [Full Text] [Related]

  • 9. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW, Suh C, Lee JS, Kim WK, Lee YS, Kim SH.
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [Abstract] [Full Text] [Related]

  • 10. A case of veno-occlusive disease complicated by severe hemorrhagic cystitis successfully treated with recombinant plasminogen activator.
    Arsène O, Delain M, Linassier C, Bremond JL, Colombat P.
    Hematol Cell Ther; 1997 Aug; 39(4):205-7. PubMed ID: 9352329
    [Abstract] [Full Text] [Related]

  • 11. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
    Hägglund H, Ringdén O, Ljungman P, Winiarski J, Ericzon B, Tydén G.
    Transplant Proc; 1995 Dec; 27(6):3535. PubMed ID: 8540088
    [No Abstract] [Full Text] [Related]

  • 12. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
    Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G.
    Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
    [Abstract] [Full Text] [Related]

  • 13. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.
    Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP.
    Am J Hematol; 1994 Jul; 46(3):194-8. PubMed ID: 8192148
    [Abstract] [Full Text] [Related]

  • 14. Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
    Heying R, Nürnberger W, Spiekerkötter U, Göbel U.
    Bone Marrow Transplant; 1998 May; 21(9):947-9. PubMed ID: 9613790
    [Abstract] [Full Text] [Related]

  • 15. Treatment of veno-occlusive disease of the liver with bolus tissue plasminogen activator and continuous infusion antithrombin III concentrate.
    Patton DF, Harper JL, Wooldridge TN, Gordon BG, Coccia P, Haire WD.
    Bone Marrow Transplant; 1996 Mar; 17(3):443-7. PubMed ID: 8704704
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
    Leahey AM, Bunin NJ.
    Bone Marrow Transplant; 1996 Jun; 17(6):1101-4. PubMed ID: 8807121
    [Abstract] [Full Text] [Related]

  • 17. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD, Yasui M, Yoshimoto T, Chayama K, Shimono T, Okamura T, Inoue M, Yumura-Yagi K, Kawa-Ha K.
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [Abstract] [Full Text] [Related]

  • 18. [Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation].
    Alvarez R, Bañares R, Casariego J, Echenagusía A, Simó G, Alvarez E, Serrano D, Díez-Martín JL.
    Gastroenterol Hepatol; 2000 Apr; 23(4):177-80. PubMed ID: 10863859
    [Abstract] [Full Text] [Related]

  • 19. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
    Kaleelrahman M, Eaton JD, Leeming D, Bowyer K, Taberner D, Chang J, Scarffe JH, Chopra R.
    Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
    [Abstract] [Full Text] [Related]

  • 20. Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
    Feldman L, Gabai E, Milovic V, Jaimovich G.
    Bone Marrow Transplant; 1995 Nov; 16(5):727. PubMed ID: 8547875
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.